Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia
MA Mueller, F Beutner, D Teupser, U Ceglarek… - Atherosclerosis, 2008 - Elsevier
Everolimus inhibits the mammalian target of rapamycin (mTOR) in proliferating cells. It is
widely used in transplant patients and has also been exploited by drug-eluting stents for the
treatment of cardiovascular disease. However, there is only limited data on the
pathophysiological effects of mTOR-inhibitors on the vascular wall. We aimed to unravel the
effects of everolimus on cholesterol-induced atherosclerosis and on circulating cell
mediators in LDL-receptor-deficient (LDLR−/−) mice. Male hypercholesterolemic LDLR …
widely used in transplant patients and has also been exploited by drug-eluting stents for the
treatment of cardiovascular disease. However, there is only limited data on the
pathophysiological effects of mTOR-inhibitors on the vascular wall. We aimed to unravel the
effects of everolimus on cholesterol-induced atherosclerosis and on circulating cell
mediators in LDL-receptor-deficient (LDLR−/−) mice. Male hypercholesterolemic LDLR …